• Putting Mammalian Embryonic Cells into Dormancy

  2026-09-25

  A Nature Protocols paper describes reversible, in vitro induction of a diapause-like state in mouse blastocysts, human blastoids and mouse or human pluripotent stem cells using pharmacological mTOR inhibition. The workflow provides a scalable alternative to invasive in vivo models for studying embryonic dormancy, while emphasizing that dormancy must be assessed through both state maintenance and the capacity to resume development.

• LY-411575: Potent Gamma-Secretase Inhibitor

  2026-09-25

  LY-411575 is a potent gamma-secretase inhibitor used to study amyloid beta production and Notch signaling pathway inhibition. Product information reports subnanomolar activity in membrane-based and cell-based assays, while a 2024 TNBC study supplies a separate rationale for investigating Notch inhibition in cancer research—not proof that LY-411575 itself improves cancer treatment.

• EZ Cap™ Cy5 EGFP mRNA for LNP Assays

  2026-09-24

  Use a single dual-fluorescence reporter to separate mRNA uptake from downstream EGFP expression when comparing delivery formulations. This practical guide shows how to pilot the reporter in nanoparticle workflows, interpret its signals, and troubleshoot common assay gaps without treating fluorescence as proof of intact RNA or therapeutic performance.

• 10058-F4: c-Myc-Max Inhibition in Practice

  2026-09-24

  Use 10058-F4 to test how disrupting c-Myc:MAX affects transcription, cell fate, and apoptosis—with distinct workflows for cancer models and TERT-focused stem-cell research. Practical dose-finding, formulation, and troubleshooting guidance helps separate target-linked effects from vehicle or general toxicity.

• Angiotensin 1/2 (5-7): Designing Better Binding Assays

  2026-09-23

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide with emerging relevance to receptor-resolved SARS-CoV-2 spike binding studies. This guide interprets the evidence, clarifies what binding assays can establish, and outlines practical choices for rigorous peptide experiments.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-09-23

  Angiotensin 1/2 (5-7) is more than a short renin-angiotensin system fragment: it is a defined molecular probe for connecting peptide sequence, cardiovascular signaling, and emerging spike-protein binding biology. This article examines its mechanistic rationale, assay strategy, translational value, and limitations for researchers designing reproducible hypertension and cross-domain studies.

• MMV Pandemic Response Box: Antimicrobial Screening Findings

  2026-09-22

  This study systematically screened compounds from the MMV Pandemic Response Box against multidrug-resistant bacterial and clinically relevant fungal isolates, combining MIC testing with a bacterial persister assay. Its findings prioritize epetraborole, eravacycline, MMV compounds, and several antifungal agents for follow-up while illustrating how early phenotypic screening can distinguish growth inhibition from fungicidal or bactericidal activity.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-09-22

  Build a rapid cell apoptosis assay around phosphatidylserine exposure and membrane integrity, with practical guidance for flow cytometry and fluorescence microscopy. The workflow connects Annexin V-Cy5/DAPI phenotyping to the P2RX1–CaMKII–PI3K/Akt apoptosis model in Ph+ ALL while clarifying controls, interpretation, and troubleshooting.

• APEX2 Enables Efficient TERT Expression in hESCs

  2026-09-21

  This bioRxiv study identifies APEX2, but not its paralog APEX1, as a contributor to efficient TERT expression and telomerase activity in human embryonic stem cells. RNA sequencing and chromatin immunoprecipitation connect this effect to repeat-rich genomic regions, especially MIR sequences within TERT intron 2, suggesting that DNA repair at repetitive elements can influence gene expression.

• Angiotensin 1/2 (5-7): Assay Design Guide

  2026-09-21

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide for fragment-aware renin-angiotensin system research. This guide translates recent spike–receptor binding evidence into practical decisions for cardiovascular, hypertension, and cross-domain assays.

• Faropenem Sodium: Penem Antibiotic Evidence

  2026-09-20

  Faropenem sodium is a penem antibiotic that supports inhibition of bacterial cell wall synthesis through penicillin-binding protein engagement. Product data describe broad Gram-positive, Gram-negative, and anaerobic activity, while peer-reviewed transporter research links faropenem renal secretion to Npt1.

• From RNA Condensates to Fluorescent Probe Strategy

  2026-09-19

  A mechanistic and translational framework for using Cy5-labeled RNA probes to investigate viral RNA biology, connect liquid–liquid phase separation findings to measurable assays, and select a flexible T7-based labeling workflow.

• HIV-1, Nuclear Pores, and T-Cell Permissivity

  2026-09-18

  The reference study identifies nuclear pore complex licensing as a decisive barrier to HIV-1 infection of resting CD4+ T cells. It shows that Env-dependent cell-cell contact activates CD4-LCK-CDK1 signalling, remodels nucleoporins, and promotes capsid nuclear import without requiring cell-cycle entry, explaining why virological synapses are highly efficient routes of transmission.

• Ampicillin sodium: Assays, Workflows & Troubleshooting

  2026-09-18

  Build more reproducible antibacterial activity assays with a research-grade β-lactam antibiotic, from stock preparation through MIC and time-kill analysis. This guide also shows how to use resistance-aware controls, comparative study design, and stability practices to improve bacterial infection model data.

• The Translational Logic of Dual-Readout mRNA

  2026-09-17

  A mechanistic and strategic guide to using EZ Cap™ Cy5 EGFP mRNA (5-moUTP) as a dual-readout benchmark for delivery, intracellular trafficking, translation, and nanoparticle development.

7863 records 1/525 page Next 12345 下5页 Last page